Table 3. Sociodemographic variables associated with use of second-line therapy among participants with self-reported coronary heart disease.
| Other antiplatelet | ARB | Fibrate | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
P-value |
|
|
P-value |
|
|
P-value | |
| Age (mean, SD) | 60.3 (8.0) | 64.4 (7.5) | < 0.0001 | 60.1 (8.0) | 64.3 (7.4) | < 0.0001 | 60.9 (8.1) | 60.3 (5.6) | 0.873 |
| Age stratum (%) | |||||||||
| 35-44 | 7 (2.0) | 0 (0.0) | 0.001 | 7 (1.7) | 0 (0.0) | 0.001 | 7 (1.8) | 0 (0.0) | 0.670 |
| 45-54 | 78 (22.3) | 8 (14.5) | 77 (23.2) | 9 (12.5) | 85 (21.4) | 1 (16.7) | |||
| 55-64 | 157 (45.0) | 15 (27.3) | 148 (44.6) | 24 (33.3) | 168 (42.2) | 4 (66.7) | |||
| 65-74 | 107 (30.7) | 32 (58.2) | 100 (30.1) | 39 (54.2) | 138 (34.7) | 1 (16.7) | |||
| Sex (%) | |||||||||
| Male | 214 (61.3) | 42 (76.4) | 0.031 | 215 (64.8) | 41 (56.9) | 0.212 | 252 (63.3) | 4 (66.7) | 0.866 |
| Female | 135 (38.7) | 13 (23.6) | 117 (35.2) | 31 (43.1) | 146 (36.7) | 2 (33.3) | |||
| Race (%) | |||||||||
| White | 173 (50.4) | 39 (73.6) | 0.034 | 179 (54.7) | 33 (47.8) | 0.319 | 208 (53.2) | 4 (40.0) | 0.771 |
| Mixed | 90 (26.2) | 8 (15.1) | 74 (22.6) | 24 (34.8) | 97 (24.8) | 1 (20.0) | |||
| Black | 64 (18.7) | 5 (9.4) | 59 (18.0) | 10 (14.5) | 69 (17.6) | 0 (0.0) | |||
| Asian | 8 (2.3) | 1 (1.9) | 8 (2.4) | 1 (1.4) | 9 (2.3) | 0 (0.0) | |||
| Indigenous | 8 (2.3) | 0 (0.0) | 7 (2.1) | 1 (0.3) | 8 (2.0) | 0 (0.0) | |||
| Education (%) | |||||||||
| Less than high school | 112 (32.1) | 2 (3.6) | < 0.0001 | 90 (27.1) | 24 (33.3) | 0.108 | 112 (28.1) | 2 (33.3) | 0.917 |
| High school and some college/university | 81 (23.2) | 13 (23.6) | 84 (25.3) | 10 (13.9) | 93 (23.4) | 1 (16.7) | |||
| Completed college/university or more | 156 (44.7) | 40 (72.7) | 158 (47.6) | 38 (52.8) | 193 (48.5) | 3 (50.0) | |||
| Income (%) | |||||||||
| ≤ USD 1,245 | 114 (32.8) | 7 (13.0) | < 0.0001 | 102 (30.8) | 19 (26.8) | 0.712 | 119 (30.1) | 2 (33.3) | 0.716 |
| USD 1,246 to 3,319 | 115 (33.0) | 12 (22.2) | 102 (30.8) | 25 (35.2) | 126 (31.8) | 1 (16.7) | |||
| ≥ USD 3,320 | 119 (34.2) | 35 (64.8) | 127 (38.4) | 27 (38.0) | 151 (38.1) | 3 (50.0) | |||
| Private health insurance (%) | 227 (65.0) | 44 (80.0) | 0.028 | 211 (63.6) | 60 (83.3) | 0.001 | 267 (67.1) | 4 (66.7) | 0.983 |
| Medication adherence (%) | |||||||||
| Adherent | 133 (42.4) | 30 (55.6) | 0.71 | 131 (44.3) | 32 (44.4) | 0.977 | 161 (44.5) | 2 (33.3) | 0.586 |
| Non-adherent | 181 (57.6) | 24 (44.4) | 165 (55.7) | 40 (55.6) | 201 (55.5) | 4 (66.7) | |||
ARB = angiotensin receptor blockers; SD = standard deviation; USD = United States dollars.